Kura Oncology to partner with Kyowa Kirin for blood cancer therapy-February 2024-www.financetom.com

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024 7:32 PM

Nov 20 (Reuters) - Kura Oncology ( KURA ) said on

Wednesday it will collaborate with Japan's Kyowa Kirin ( KYKOF )

to develop and commercialize the blood cancer therapy

ziftomenib.

Kura said it will receive an upfront payment of $330 million

and up to $1.2 billion in total milestone payments as part of

the deal.

Previous page： D.R. Horton's Fiscal Q2 Earnings, Revenue Advance; 2024 Revenue Outlook Raised -- Shares Up Pre-Bell Next page： Genuine Parts' Q1 Adjusted Earnings, Net Sales Increase; 2024 Outlook Updated

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

D.R. Horton's Fiscal Q2 Earnings, Revenue Advance; 2024 Revenue Outlook Raised -- Shares Up Pre-Bell

Apr 18, 2024

07:01 AM EDT, 04/18/2024 (MT Newswires) -- D.R. Horton ( DHI ) reported fiscal Q2 earnings Thursday of $3.52 per diluted share, up from $2.73 a year earlier. Analysts polled by Capital IQ expected $3.05. Revenue for the quarter ended March 31 was $9.11 billion, up from $7.97 billion a year earlier. Analysts surveyed by Capital IQ expected $8.23 billion....

Genuine Parts' Q1 Adjusted Earnings, Net Sales Increase; 2024 Outlook Updated

Apr 18, 2024

07:18 AM EDT, 04/18/2024 (MT Newswires) -- Genuine Parts ( GPC ) reported Q1 adjusted earnings Thursday of $2.22 per diluted share, up from $2.14 a year earlier. Analysts polled by Capital IQ expected $2.16. Net sales for the quarter ended March 31 were $5.78 billion, up from $5.77 billion a year earlier. Analysts surveyed by Capital IQ expected $5.84...

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing

Apr 18, 2024

07:22 AM EDT, 04/18/2024 (MT Newswires) -- Richard E Lowenthal, 10% Owner, Director, PRESIDENT AND CEO, on April 16, 2024, sold 100,000 shares in ARS Pharmaceuticals ( SPRY ) for $928,005. Following the Form 4 filing with the SEC, Lowenthal has control over a total of 12,546,116 shares of the company, with 4,126,822 shares held directly and 8,419,294 shares controlled...

Awale Resources to Raise $10 Million in Bought Deal Private Placement

Apr 18, 2024

07:17 AM EDT, 04/18/2024 (MT Newswires) -- Awale Resources ( AWLRF ) , which lost 14% yesterday, overnight Wednesday said it will raise about $10 million in a bought deal private placement. The company, will will use the funds for its projects in Cote d'Ivoire and for general corporate purposes, will sell roughly 16.1 million units to a syndicate of...